Conference call scheduled to begin at 4:30 PM ET
SOUTH SAN FRANCISCO, Calif., March 7, 2024 (Globe Newswire) — Vaxart, Inc. (NASDAQ: VXRT) today provides an after-market business update and forecasts for the full year ending December 31, 2023. announced that it will report its financial results. The Vaxart senior management team will host a conference call on the same day at 4:30pm ET.
You can access the conference call using the following information:
Webcast: Click here
Date: Thursday, March 14, 2024 – 4:30 PM ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13744368
Investors may submit written questions to ir@vaxart.com prior to the conference call.
After the event, a replay of the webcast will be available for viewing on our website www.vaxart.com.
About Bakart
Vaxart is a clinical-stage biotechnology company developing a variety of oral recombinant vaccines based on proprietary delivery platforms. The Vaxart vaccine is designed to be administered using tablets that can be stored and transported without refrigeration and eliminate the risk of needle stick injuries. Vaxart believes that its proprietary pill vaccine delivery platform is suitable for the delivery of recombinant vaccines, and the company will develop oral versions of currently commercially available vaccines and develop recombinant vaccines for new indications. We are in a position to design. Currently, Vaxart's development programs include tablet vaccines designed to protect against coronaviruses, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. It is. Vaxart has extensive domestic and international patent applications covering proprietary technology and products for oral vaccination using adenoviruses and his TLR3 agonists.
contact address
|
Vaxart Media Relations: |
Public relations activities for investors: |
